H3 Biomedicine CEO and leadership

Ping joined H3 in 2012 and is currently President and Chief Scientific Officer and serves as an executive leadership team member. Ping brings more than 15 years of experience in cancer research and drug discovery to H3, where he has held positions of increasing scientific and management responsibility. At H3, his group aims to discover next-generation anti-cancer medicines by targeting highly validated molecular targets based upon genomics, transcriptomics and functional data, using systematic approaches. Prior to joining H3, Ping was a group leader at Novartis Institutes for Biomedical Research, where he worked on early drug discovery and target identification and validation in oncology, leading multidisciplinary teams across multiple geographic locations. In 2010, he earned the Novartis Catalyst Award for cancer drug discovery innovation. His research has been published in leading scientific journals including Cell, Nature, Cancer Discovery, Cancer Cell and Nature Communications. Ping was also a recipient of the Endocrine Scholars Award from the Endocrine Society for his scientific achievements.

Ping received his Medical Degree (B.M.) from Shanghai Second Medical University, his Ph.D. in molecular biology from the University of Karlsruhe in Germany and postdoctoral training at the Howard Hughes Medical Institute and UC San Diego.

Physician-scientist with extensive pharmaceutical R&D experience spanning from compound lead selection to drug registration. Head of the Clinical R&D function. Proven success devising clinical R&D strategies and managing portfolio execution for over 20 years at multiple biopharma companies.

Peter G Smith is a Chief Scientific Officer at H3 Biomedicine Inc. He has experience at MILLENNIUM PHARMACEUTICALS and has worked as VP: Drug Discovery Biology at H3 Biomedicine Inc and Dir:Target Biology at H3 Biomedicine Inc. Peter attended University of Sheffield and University of Newcastle.

Terushige Iike are a Chief Executive Officer at H3 Biomedicine Inc and Pres:Oncology at Eisai Co. Ltd.. They have worked as Senior Vice President at Eisai Co. Ltd. and General Manager at Eisai Co. Ltd..